Neuroendocrine carcinoma begins in the neuroendocrine cells and can metastasize to other parts of the body. It develops in the hormone producing cells of the body’s neuroendocrine system. Neuroendocrine carcinoma can develop in many organs, including gastrointestinal tract, lungs and brain. The risk factors associated with neuroendocrine cancer include, family history, immune system suppression, sun exposure and arsenic exposure. An increasing awareness regarding cancer, various advancements, and high prevalence of cancer, are some of the factors driving the growth of the neuroendocrine carcinoma pipeline. Ipsen Group is in the process of developing OPS201 as somatostatin receptor 2 antagonists for the treatment of neuroendocrine carcinoma. Some of the companies having a pipeline of neuroendocrine carcinoma include Ipsen Group, Provectus Biopharmaceuticals, Inc., AbbVie Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all the drug candidates under various stages of development. This report provides a global outline about the therapeutics pipeline of the disease, with detailed analysis of pipeline and clinical trials. The pipeline analysis of drugs by phases includes information related to product description and other development activities, such as information with respect to designations, collaborations, licensing, grants, funding, and technology.